Should you buy AbbVie stock now?
Yes, the technical signal for AbbVie is currently BUY. AbbVie trades at $242.77 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.648 with falling momentum (signal: 5.110); RSI is at 47.5 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $272.18 points to 12.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for AbbVie stock?
The average analyst price target for AbbVie is $272.18. The current price is $242.77, which gives an upside of 12.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $244.96 and $299.40.
Is AbbVie a dividend stock?
Yes, AbbVie is a dividend stock with a dividend yield of 2.79%. The latest dividend was $1.73 per share. The latest ex-dividend date (traded without the dividend) was 7/15/2026. The payout ratio is 62.8%, which is considered moderate. The next dividend payment is scheduled for 8/14/2026.
When does AbbVie pay a dividend in 2026?
AbbVie pays its next dividend on 8/14/2026. The latest dividend was $1.73 per share with an ex-dividend date of 7/15/2026. The dividend yield is 2.79%. The payout ratio of 62.8% points to moderate dividend coverage.
What is the risk of AbbVie stock?
AbbVie is rated as a stock with moderately low risk. the annual standard deviation is 26.1%, which classifies the stock as moderately low risk.
Is AbbVie overvalued?
No, AbbVie is considered undervalued based on the analyst price target (12.1% upside). AbbVie has the following valuation ratios: a P/E ratio of 68.9 (highly valued), a P/S ratio of 6.7, a P/B ratio of 50.5. The analyst price target suggests that the stock is undervalued by 12.1%.
Is AbbVie overbought?
No, AbbVie is not overbought. RSI is at 47.5 (neutral zone). The technical indicators show: RSI is at 47.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.7% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next AbbVie earnings report?
The date of the next earnings report for AbbVie has not been published yet. Check the company's investor calendar for updates.
Is AbbVie shorted?
Yes, AbbVie is shorted with 1.4% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying AbbVie stock?
No, insiders are not buying AbbVie shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 80,601,225 $ sold. Active sellers include Purdue David Ryan, David Ryan Purdue, Siatis Perry C and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is AbbVie a good stock?
Based on our total score, AbbVie is rated as a mediocre stock with a total score of 59 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 12/100, Quality: 88/100, Momentum: 78/100. In addition: analysts see 12.1% upside to the price target; a dividend of 2.79%; technical signal: Strong Buy. Whether AbbVie is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for AbbVie stock?
The outlook for AbbVie based on current data: the average analyst price target is $272.18 (+12.1%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 68.9 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is AbbVie stock falling?
AbbVie is falling right now. The technical indicators show: the price is 3.7% below the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can AbbVie go?
The average analyst price target for AbbVie is $272.18, which corresponds to a potential gain of 12.1% from the current price of $242.77. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can AbbVie fall?
We lack enough history to give a specific floor for AbbVie. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does AbbVie do?
AbbVie er et stort medicinalselskab, der udvikler, fremstiller og sælger lægemidler globalt. De tjener primært penge på at levere behandlinger inden for en række sygdomsområder. Virksomheden startede i 2012 og har hovedkontor i North Chicago.
AbbVie er især kendt for deres st... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate AbbVie as an investment.
Did AbbVie raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from AbbVie. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is AbbVie making money or losing money?
Yes, AbbVie is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 9.8% — which is moderate. The operating margin (profit before interest and taxes) is 39.6%. At a P/E ratio of 68.9, you currently pay 68.9 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can AbbVie go bankrupt?
The bankruptcy risk of AbbVie is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.41 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 3,918% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does AbbVie have a lot of debt?
Yes, AbbVie has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 3,918%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
